Hims & Hers Health (HIMS)
Connects personalized treatment plans with telehealth consultations and pharmacy fulfillment.
Something off on this page? Send us feedback.
Provides direct-to-consumer care across weight loss, hair regrowth, sexual health, dermatology, mental health, hormone health, and preventive testing. Recurring treatment plans connect digital intake, affiliated-provider consultations, prescriptions, and pharmacy fulfillment, with the United States as the core market and an expanded international footprint.
Sells personalized care for weight loss, hair regrowth, sexual health, dermatology and skincare, mental health, hormone health, and preventive testing through websites and mobile apps. Customers pay directly for prescription and nonprescription products, laboratory services, and recurring treatment plans that include provider follow-up.
Combines consumer marketing, digital intake, telehealth, electronic records, and predominantly owned-pharmacy fulfillment in one integrated operating model. The United States remains the core market; ZAVA, Livewell, and Eucalyptus extend the platform across the United Kingdom, Australia, Canada, parts of Europe, and Japan.
Clinical care in the United States is delivered by separately owned affiliated medical groups. Operations depend on licensed providers, pharmaceutical supply and fulfillment, and changing rules governing telehealth, prescribing, pharmacy practice, privacy, and compounded medications.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 24, 2026 | Truist Financial | Target | Target: $18 | Target: $32 |
| Aug 20, 2026 | Barclays | Reiterate | Rating: —Target: $39 | Target: $35 |
| Aug 11, 2026 | Deutsche Bank | Reiterate | Rating: —Target: $25 | Target: $26 |
| Aug 11, 2026 | Needham | Reiterate | Rating: —Target: $30 | Target: $42 |
| Aug 11, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $21 | Target: $28 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $841.0M · Total debt $1.55B · Total assets $3.63B · Shareholders' equity $324.1M
- Revenue
- $753.2M
- Operating income
- −$97.2M
- Net income
- −$86.3M
No dividends on record.
| Institutions | 67.87% | 158.34M shares | |
|---|---|---|---|
| 586 holders · as of Jun 30, 2026 | |||
| Insiders | 37.97% | 88.60M shares | |
| 19 holders · as of Sep 18, 2026 | |||
| Strategic holders | 6.22% | 14.50M shares | |
| 1 holder · as of May 15, 2026 | |||
| Adds to | 112.06% | ||
233.31M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 112.06%; nothing is left for Other.
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Andrew Dudum1,2Insiderdirector, 10 percent owner, officer: Chief Executive Officer | 14.17% | 34.80M A | filed Aug 27, 2026 |
BlackRock, Inc.Institution | 12.30% | 28.70M A | as of Jun 30, 2026 |
Jack Abraham3,4Insider10 percent owner | 9.96% | 24.21M A | filed Dec 16, 2021 |
Ravi ViswanathanInsider | 6.33% | 14.78M | filed Feb 1, 2021 |
Ravi Viswanathan (“Viswanathan”)Insider | 6.31% | 14.72M | filed Feb 14, 2023 |
- Andrew Dudum's transaction reports restate only vehicles that traded; the 2021 ownership statement (34.80M) less the 1.73M net shares sold since is used instead.
- Andrew Dudum reports a block also reported by another filer; it is counted once, under that filer.
- Jack Abraham's transaction reports restate only vehicles that traded; the 2021 ownership statement (24.21M) less the 964.1K net shares sold since is used instead.
- Jack Abraham reports a block also reported by Morgan Stanley; it is counted once, under Morgan Stanley.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 17, 2026 | Oluyemi Okupe | officer: Chief Financial Officer | −12,313 | $28.82 |
| Sep 15, 2026 | Mohamed Elshenawy | officer: CTO | −7,954 | $28.39 |
| Sep 15, 2026 | Michael Chi | officer: Chief Operating Officer | −14,027 | $28.39 |
| Sep 16, 2026 | Soleil Boughton | officer: Chief Legal Officer | −6,236 | $27.86 |
| Sep 2, 2026 | Soleil Boughton | officer: Chief Legal Officer | −3,458 | $28.33 |
- LifeMD
Closest public DTC telehealth peer in weight loss and men's health
- GoodRx
Prescription-access platform moving into DTC condition subscriptions
- Teladoc Health
Virtual-care incumbent with integrated care and mental-health scale
- Novo Nordisk (ADR)
Branded semaglutide maker attacking compounded GLP-1 demand
- Amazon
Consumer-scale virtual care and pharmacy delivery challenger
- Eli Lilly
Tirzepatide leader using LillyDirect to bypass intermediaries
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Hims & Hers Health | $29.37 | −3.50% | $6.79B | — | 136.6 | 2.6 | +38.3% |
| LifeMD | $3.16 | −4.39% | $159.6M | — | — | 0.8 | −24.0% |
| GoodRx | $3.40 | −1.16% | $1.19B | 80.9 | 10.0 | 1.5 | −1.3% |
| Teladoc Health | $6.22 | −2.05% | $1.15B | — | — | 0.5 | −4.0% |
| Novo Nordisk (ADR) | $38.75 | −1.66% | $174.96B | 9.9 | 16.0 | 3.5 | +1.3% |
| Amazon | $249.41 | −2.18% | $2.74T | 20.5 | 26.7 | 3.5 | +19.6% |
| Eli Lilly | $1,161.91 | −0.70% | $1.10T | 39.3 | 28.4 | 13.8 | +47.7% |
| Median | 29.9 | 21.3 | 2.5 | −0.0% |